Literature DB >> 26047704

Isopentenyl pyrophosphate secreted from Zoledronate-stimulated myeloma cells, activates the chemotaxis of γδT cells.

Eishi Ashihara1, Tatsuya Munaka2, Shinya Kimura3, Saori Nakagawa4, Yoko Nakagawa5, Masaki Kanai2, Hideyo Hirai5, Hirohisa Abe2, Takashi Miida6, Susumu Yamato4, Shuichi Shoji7, Taira Maekawa5.   

Abstract

γδT cell receptor (TCR)-positive T cells, which control the innate immune system, display anti-tumor immunity as well as other non-immune-mediated anti-cancer effects. γδT cells expanded ex vivo by nitrogen-containing bisphosphonate (N-BP) treatment can kill tumor cells. N-BP inhibits farnesyl pyrophosphate synthase in the mevalonate pathway, resulting in the accumulation of isopentenyl pyrophosphate (IPP), which is a stimulatory antigen for γδT cells. We have previously observed that as they get closer, migrating γδT cells increase in speed toward target multiple myeloma (MM) cells. In the present study, we investigated the γδT cell chemotactic factors involving using a micro total analysis system-based microfluidic cellular analysis device. The addition of supernatant from RPMI8226 MM cells treated with the N-BP zoledronic acid (ZOL) or the addition of IPP to the device induced chemotaxis of γδT cells and increased the speed of migration compared to controls. Analysis of the ZOL-treated RPMI8226 cell supernatant revealed that it contained IPP secreted in a ZOL-dose-dependent manner. These observations indicate that IPP activates the chemotaxis of γδT cells toward target MM cells treated with ZOL.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chemotaxis; Isopentenyl pyrophosphate; Multiple myeloma; Tumor immunity; γδT cells

Mesh:

Substances:

Year:  2015        PMID: 26047704     DOI: 10.1016/j.bbrc.2015.05.118

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

1.  Low dose gemcitabine increases the cytotoxicity of human Vγ9Vδ2 T cells in bladder cancer cells in vitro and in an orthotopic xenograft model.

Authors:  Teruki Shimizu; Mako Tomogane; Masatsugu Miyashita; Osamu Ukimura; Eishi Ashihara
Journal:  Oncoimmunology       Date:  2018-02-08       Impact factor: 8.110

2.  Folate-targeted pH-responsive calcium zoledronate nanoscale metal-organic frameworks: Turning a bone antiresorptive agent into an anticancer therapeutic.

Authors:  Kin Man Au; Andrew Satterlee; Yuanzeng Min; Xi Tian; Young Seok Kim; Joseph M Caster; Longzhen Zhang; Tian Zhang; Leaf Huang; Andrew Z Wang
Journal:  Biomaterials       Date:  2015-12-20       Impact factor: 12.479

3.  A Mathematical Model of In Vitro Cellular Uptake of Zoledronic Acid and Isopentenyl Pyrophosphate Accumulation.

Authors:  Elena Lo Presti; Laura D'Orsi; Andrea De Gaetano
Journal:  Pharmaceutics       Date:  2022-06-14       Impact factor: 6.525

Review 4.  γδ T Cells in the Tumor Microenvironment-Interactions With Other Immune Cells.

Authors:  Kok Fei Chan; Jessica Da Gama Duarte; Simone Ostrouska; Andreas Behren
Journal:  Front Immunol       Date:  2022-07-11       Impact factor: 8.786

Review 5.  Advanced Cell Therapies for Glioblastoma.

Authors:  Guangwen Wang; Wenshi Wang
Journal:  Front Immunol       Date:  2022-08-16       Impact factor: 8.786

Review 6.  Gamma Delta T Cell Therapy for Cancer: It Is Good to be Local.

Authors:  C David Pauza; Mei-Ling Liou; Tyler Lahusen; Lingzhi Xiao; Rena G Lapidus; Cristiana Cairo; Haishan Li
Journal:  Front Immunol       Date:  2018-06-08       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.